티디에스팜

464280KOSDAQ의약품 제조업

64.3 / 100

Reference Date: 2026-06-10

Financial Score30.0 / 40

News Sentiment21.3 / 25

Momentum3.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but Revenue metrics are weak. Plunged 23.1% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

TDS Pharm specializes in the development and manufacturing of transdermal drug delivery systems (TDDS), holding a leading position in the Korean market with key products like Cataplasma and Plaster. The company aims to grow into a global pharmaceutical firm by expanding its portfolio to include patches targeting dementia, asthma, nicotine addiction, and other therapeutic areas.

Number of Employees

111people

Average Salary

32.1M KRW

Score Calculation Basis

Detailed Financial Score

PER

8.38Industry Average 11.936.5Point

Lower than industry avg (good)

PBR

0.84Industry Average 0.894.0Point

In line with industry avg

ROE

10.52Industry Average 4.017.0Point

2.6x industry avg (excellent)

Debt Ratio

0.38Industry Average 12.438.0Point

Half of industry avg (excellent)

Trend 2024~20254.5 / 10 points

Revenue Growth Rate

1.0 / 3

Avg ▲0.4% (1-year basis)

Operating Profit Growth Rate

1.0 / 3

Avg ▲0.9% (1-year basis)

ROE Trend

2.5 / 4

Avg ROE 11.3% (declining, 2yr)

Detailed News Sentiment

1 totalPositive 1Neutral 0Negative 0Average Sentiment Score 85

Positive
티디에스팜, 1분기 매출 50% 성장…"신규 거래처 확대 효과"
티디에스팜의 1분기 매출이 전년 동기 대비 50% 이상 증가하여 긍정적인 실적을 발표했다.

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 6,480Won52-week high 11,89052-week low 6,480

1-month return0.0Point

1m -23.13% (strong drop)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

1 totalPositive 0Neutral 1Negative 0

Neutral분기보고서 (2026.03)2026-05-14